



TARPSWG Semi-annual Virtual Meeting Minutes

Wednesday March 17, 2020, 8-11am

Attendees: Dagmar Adamkova Krakorova, Samuel Aguiar, Markus Albertsmeier, Max Almond, Eisar Al-Sukhni, Christina Angeles, José Manuel Asencio, Salvatore Asero, Yael Babichev, Marc Bemelmans, Dan G. Blazer III, Sylvie Bonvalot, Meni Brakha, Savtaj Brar, Sally Burtenshaw, Dario Callegaro, Ferdinando Cananzi, Ken Cardona, Sergio Cervera-Bonilla, Jun Chen, Tom Wei-Wu Chen, Luo Cheng Hua, Peter Chong, David Coker, Sarah Corn, Aimee M Crago, Cathy Davidson, Nicolas Devaud, Palma Dileo, Sinziana Dumitra, Lilian María Escobar Lezcano, Mark Fairwhethear, Jeffrey Farma, Marco Fiore, Samuel Ford, Dorian Yarih García Ortega, Rebecca Gladly, Mahesh Goel, Ricardo Gonzalez, José Antonio González, Stephanie Greco, Jonathan Greer, Giovanni Grignani, Valerie Grignol, Alessandro Gronchi, Abha Gupta, David Gyorki, Peter Hohenberger, Angela Hong, Paul Huang, Shintaro Iwata, Wendy Johnston, Bernd Kasper, Raymond Kennedy, Theresa Kim, Nicole Larrier, Peter Lee, Hassan Malik, Joshua Mammen, Gary Mann, Alejandra Mantilla, Pedro Martins, Skye Mayo, Nikolaos Memos, John Mullinax, Deanna Ng, Maxim Nikulin, Marko Novak, Emanuela Palmerini, Sandro Pasquali, Shraddha Patkar, Elisabetta Pennacchioli, Andraz Perhavec, Francisco Manuel Perrotta Martínez, Andrea Porpiglia, Sergio Damián Quildrian, Martha Quinn, Stefano Radaelli, Chandrajit Raut, Salvatore Renne, Christina Roland, Lorella Rusi, Piotr Rutkowski, Roberta Sanfilippo, Catherine Sarre, Raza Sayyed, Yvonne Schrage, Sergei Sichachov, Jason Sicklick, Hayden Snow, Gaya Spolverato, Malcom Squires, Stephan Stoldt, Dirk Strauss, Carol Swallow, Anastasia Tararykova, Fabio Tirota, William Tseng, Dimitri Tzanis, Winette Van der Graaf, Jos van der Hage, Winan Van Houdt, Gabrielle H. van Ramshorst, Nikolaos Vassos, Anthony Visioni, Claire Wunker, Celso Mello, Ali Samkari, Jennifer Dorsey, James Glasbey, Mycos Leandro Zapata, Radim Simunek, Piotr Kobiela.

Apologizes: Erwin Ricardo Flores Vázquez, Annamaria Frezza, Rick Haas, Attila Kollar, Carolyn Nessim, Elena Palassini, Silvia Stacchiotti, Eva Wardelmann

- **Introduction** by Alessandro Gronchi (5 mins) welcome to the third virtual TARPSWG meeting and discusses recent updated guidelines and accepted manuscripts from the group.
 - Updated recommendations about the management of primary RPS accepted by Ann Surg Oncol
 - L Pancreatectomy in multivisceral resection for primary RPS accepted by Ann Surg Oncol
 - Mesenteric Sarcoma accepted by J Surg Oncol
 - Invited review about the TARPSWG program on Curr Opin Oncol
 - Change in differentiation in recurrent Liposarcoma resubmitted to Ann Surg Oncol with minor revision
 - Postnephrectomy Outcomes Following en bloc Resection of Primary Retroperitoneal Sarcoma (RPS) resubmitted to Br J Surg after 1st round of revisions
 - Dynamic nomogram in RPS submitted to Clin Cancer Res
 - Data Dissemination of the Role of Neoadjuvant Radiation in Retroperitoneal Sarcoma presented at this year SSO annual meeting and being submitted to Ann Surg Oncol
 - Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: EORTC trial (STRASS) vs off-trial (STREXIT) results is being circulated in these weeks and will be submitted to Lancet Oncol
 - STREXIT manuscript about the description of the cohort vis a vis STRASS and reasons for not including patients is being drafted and will be circulated soon.
- **Update STRASS 2** (15 mins)-
 - Site activation and accrual status (W. van Houdt)
 - Currently 13 sites activated in Europe, n=5 patients accrued
 - Akynzeo sub-study was cancelled due to withdrawal from the company.
 - Update from Australia, Canada, US, Japan (R. Gladly, K. Cardona, D. Gyorki)



- US: progress as protocol approved by the board, FSA expected by the end of the year
 - Canada: Central EC approval received Feb 2021, FSA expected in a couple of weeks, expect 5 sites to activate. Centralized through CCTG
 - Australia: contract in progress, hope to open 3 sites and achieve internal funding. Aiming to open the 2nd half of the year.
 - Japan: first meeting took place to initiate the collaboration. JCOG board still needs to approve study, FSA expected in 1.5 years
- Q&A for participating centers: There are no extra funds to open other sites/countries if not already planned. However if countries/sites not included were able to find funds to support their participation (which will have to include also EORTC HQs costs), a discussion could be initiated.
- **STREXIT- CP Raut, CJ Swallow (10 mins)**
 - STRASS 190 patients and STREXIT 831
 - Analysis of
 - Overall survival
 - Abdo recurrence free survival
 - Found no significant difference between STRASS and STREXIT by these two features
 - Goal to do a similar analysis using RESAR vs STRASS2
- **SARveillance Trial (SART) Update- S Ford (10 mins)**
 - International partially randomized patient preference trial of high vs low surveillance
 - Run as a trial within the registry, with a multidisciplinary development team
 - Currently 22 international participating sites, funding through a Royal College grant to run and adopted by CRCTU (Cancer Research Clinical Trials Unit) in the UK.
 - Primary outcome changed from OS to Quality Adjusted life years (QALY)
 - Patient preference arm added- for those patients who declined to be randomized but offer to participate can do so through this arm
 - Trial using QLQC30 for Quality of Life assessment
 - **Next step:** repower for QALYs as primary outcome, adjust protocol and formalize # per year to be recruited.
- **RESAR Update (60 mins)**
 - Update of recruitment and status of centralized RESAR data collection/registry/mechanics of registry trials-D Callegaro (7 mins)
 - Currently over 2000 patients recruited, 14% increase over 4 months (added 256 patients from Sept 2020)
 - New RESAR centres:
 - 2 recruiting
 - 5 ready to recruit
 - 2 protocol submitted to IRB
 - Currently ½ of the recruitment is by 8 high volume centres
 - Revisiting the data dictionary with a focus on pathology- D Gyorki, B Dickson (15 mins)
 - Updating data fields
 - Tumor grading
 - IHC



- Subtype definition
- Ensure alignment with WHO 2020
- Discuss possible consensus statements on approach to RP sarcoma reporting
- Consider new data fields to collect to answer key questions
- **Next steps:** meeting in a few weeks, update at CTOS TARPSWG meeting
- Inclusion of Primary non resected RPS- D Strauss, CJ Swallow, W Tseng (15 mins)
 - Currently use resectable, borderline resectable and unresectable in determining resectability of case
 - Toronto study on why where non-metastatic primary RP sarcomas not resected? Found that age and multifocality were factors in non-resectable status. Those who progressed on treatment had a worse prognosis. Decision to resect based on biology, patient factors and technical factors
 - Need to standardize and 'speak the same language' when it comes to resectability
 - Discussion on inclusion of unresectable cases in RESAR (W Tseng)
 - Initially only included curative intent case, with a denominator of already resected case
 - Flowchart of data points suggested for unresectable patients including reason for unresectability (anatomic, sarcomatosis, comorbidities/PS, multifactorial), treatment given and response to treatment
 - Discussion on resectability and multifactorial reasons for resection as anatomic, patient characteristics and histology.
 - Suggestion made to create a separate database for these cases rather than incorporate into RESAR existing structure → inclusion in RESAR preferred
- **RESAR projects update**
 - Last update version of RESAR and update on the DSA Framework and information on how to be part of it – M Fiore (5 mins)
 - Currently 9 new sites in progress to join Framework Agreement
 - Joining Framework Agreement will be required to participate in ResAntiPath/BISARC/Global PoC: these 3 DTAs will be circulated together (May 2021)
 - Goal of prospective centralization for ready availability of data and data quality monitoring within end 2021
 - Creation of new online platform (with additional features such as randomization tool and pseudoanonymation) with future entry options:
 - Online direct entry
 - Upload from exiting Excel/Filemakeer local files
 - Upload from data repository system
 - RESAR open for any centre to join, contact marco.fiore@istitutotumori.mi.it or tarpswg@gmail.com
 - To join Framework agreement, contact marco.fiore@istitutotumori.mi.it



- **Planned RESAR Projects and Deadlines**
 - Complexity score project for post op morbidity- M Fairweather (2 mins)
 - No further opt-ins
 - N=1159 patients
 - Data cleaning in process for abstract at CTOS this year
 - Biopsy project (BISARC)- S Dimitra (2 mins)
 - Data collected to 2020
 - Data sharing agreements in progress, estimated timeline of April 2021
 - Correlation between anticipated resection vs actual resection (ResAntiPath) - M Fiore (2 mins)
 - Data covering timeframe of 2017-2020
 - N=19 centres have opted in
 - Data transfer deadline to Milan is June 2021
 - Variation in patterns of care (Global PoC)- H Snow (2 mins)
 - Examines consistencies of use of various diagnostic, surgical, neoadjuvant modalities
 - Eligible if entered RESAR data from Feb 2017-Jan 2020
 - No additional data points needed for this study, only RESAR data
 - For study enquiries, contact Hayden Snow at Hayden.snow@petermac.org
 - Response evaluation after neoadjuvant chemotherapy for retroperitoneal sarcoma- W Van Houdt (5 mins)
 - Role of NA chemotherapy remains unclear (role of STRASS2)
 - Primary objective: correlation between radiological and pathological response rate to neoadjuvant systemic therapy
 - Extra data required:
 - Early response evaluation during treatment
 - Response after neoadjuvant treatment
 - Benchmarks in RPS - F Tirota (5 mins)
 - Benchmarks in RP Sarcoma Surgery ("Benchmarking-> 'defining best practice'")
 - Aim: To define benchmark criteria for best achievable outcomes in RPS surgery in order to enable comparative quality assessment
 - Primary outcomes: post operative performance
 - Subset of RESAR database needed and ASA score
 - Deadline: 01-May-2021
- **REC Committee Update (30 mins)**
 - Update about REC committee functions and Terms, New members, Defining TARPSWG projects- D Gyorki (5 mins)
 - Reminder on submission:
 - Fill out an application by contacting cnessim@toh.ca
 - Application reviewed by 3-4 members of REC



- Feedback to applicant
 - Protocol Distribution
 - To join this committee, please email cnessim@toh.ca
- Desmoid project – C Nessim (2 mins)
 - Discussion deferred to next meeting
- Inguinal Sarcoma Project – S Dumitra (5 mins)
 - Definition updated to include all cord sarcomas, spermatic cord, paratesticular and inguinal sarcomas
 - Retrospective design with study closing Aug 2021
 - Guidelines goal to submit by November 2021
 - Any questions, please email sinziana.dumitra@mcgill.ca
- Update on STRASS Post-Publication Survey – C Roland (5 mins)
 - Survey in April-early May 2021 for a CTOS submission
- Ganglioneuroma project- Questions about database entry and deadline to submit data- J Sicklick (2 mins)
 - All sites at various stages of involvement
 - Deadline for data is April 1 2021
- Natural History of WD LPS Study- Questions about database entry and deadline to submit data- M Fairweather (2 mins)
 - 42 sites have agreed to participate
 - All primary surgery data
 - DTA in progress
 - Data submission deadline: April 1 2021
- PelviSarc- present data and analysis thus far- M Fiore (5 mins)
 - Interim analysis included 16 centres and 270 patients
 - 32 centres included for final analysis
 - Currently closed to opt in.
- **Clinical Trials Committee- C Roland (10 mins)**
 - Currently three projects under development:
 - Trabectedin and XRT in WDLPS and low grade DDLPS (presented by Dario)
 - Role of XRT in recurrent RPS (Angela Hong working on prospective study)
 - SBRT for abdominal recurrence- REC study to start (Andrew Bishop and Mateusz Spalek)
- **Translational Research Committee- R Gladdy (5 mins)**
 - Plan moving forward to:
 - Develop important biologic questions, protocols approved by TARPSWG
 - Participate in correlative studies
 - Translational studies with STRASS1 samples
 - LPS biology focus
 - STRASS2 Translational Research- Response to therapy needs to be evaluated
 - Need to harmonize biobanking protocols at expert centres, focus on abdominal sarcomas
 - Plan: Meeting in April 2021, questions: Rebecca.gladdy@sinaihealth.ca
- **Education Committee Update- D. Callegaro, J Farma (15 mins)**
 - Foundations and principles of Education Committee- to promote education for residents and fellows
 - Webinars



- Planned 5 webinars, starting in June and every 2 mos afterwards
 - Moderated webinars with relevant papers to be circulated ahead
 - Interaction with the group
 - **Action item:** Call out to group to participate as topic experts
- Library Project
 - List of papers on key topics available for trainees to be able to search within
- EJSO Special Issue
 - Formal invitation to contribute will be sent out
- Questions: contact Dario.Callegaro@istitutotumori.mi.it
- **TARPSWG survey- Max Almond (10 mins)**
 - Survey of 36 RESAR centres, with 86 replies
 - 94% are academic hospitals
 - 76% of centres have weekly tumour boards
 - All operate on RP Sarcoma
 - Discussion on what makes a centre of expertise?
 - # cases per year?
 - Weekly multidisciplinary tumour boards?
 - PEER Review
 - Consensus survey for a centre of excellence may be a good follow up survey to the current TARPSWG survey
- **TARPSWG photo-** The group photo will be taken and distributed to the group
- **AOB and adjournment**

Next meeting will be held hopefully in person the day before CTOS on Wednesday November 10th 2021

Additionally, RESAR Investigator's Meeting may be called sometime in June if necessary

The recorded event can be viewed on demand at the following link:
[2021 March 17th TARPSWG Semiannual Meeting Video](#)

Slides of discussed projects are available for download at:

[Meeting Slides](#)